Eliem Therapeutics, Inc.
NASDAQ:ELYM
5.11 (USD) • At close October 2, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 15.411 | 26.214 | 23.322 | 9.342 | 4.019 |
| General & Administrative Expenses
| 9.888 | 18.921 | 12.35 | 2.425 | 0.677 |
| Selling & Marketing Expenses
| 24.854 | 0 | 0 | 0 | 0 |
| SG&A
| 9.888 | 18.921 | 12.35 | 2.425 | 0.677 |
| Other Expenses
| 0 | 1.375 | -11.638 | 0 | 0.914 |
| Operating Expenses
| 37.408 | 45.135 | 35.672 | 11.767 | 4.696 |
| Operating Income
| -21.466 | -45.135 | -35.672 | -20.925 | -7.446 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -13.653 | -0.109 | -11.808 | 0.257 | 0.899 |
| Income Before Tax
| -35.119 | -45.244 | -47.48 | -20.668 | -6.547 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0.021 | 0.109 | -0.067 | -9.158 | -2.75 |
| Net Income
| -35.119 | -45.353 | -47.48 | -11.51 | -3.797 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.3 | -1.72 | -1.81 | -0.44 | -0.14 |
| EPS Diluted
| -1.3 | -1.72 | -1.81 | -0.44 | -0.14 |
| EBITDA
| -13.653 | -43.651 | -35.502 | -2.866 | -1.931 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 |